Chengcong Chen current research focuses on the clinical application of Antibody-Drug Conjugates (ADCs) in cancer treatment. His goal is to help optimise the clinical use of ADCs, thereby enhancing therapeutic efficacy and minimising adverse reactions. Furthermore, he aspire to engineer next-generation ADCs that offer superior potency and an improved safety profile.